mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia.
Rafal T
RT
Olszewski
Tomasz
T
Bzdega
Joseph H
JH
Neale
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018691:Excitatory Amino Acid Antagonists / Q000633:toxicity; D005106:Exploratory Behavior / Q000187:drug effects; D043425:Glutamate Carboxypeptidase II / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D009943:Organophosphorus Compounds / Q000633:toxicity; D010622:Phencyclidine / Q000633:toxicity; D018094:Receptors, Metabotropic Glutamate / Q000172:deficiency / Q000378:metabolism*; D012559:Schizophrenia / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics
C402107:2-(phosphonomethyl)pentanedioic acid; D014150:Antipsychotic Agents; D018691:Excitatory Amino Acid Antagonists; D009943:Organophosphorus Compounds; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; D043425:Glutamate Carboxypeptidase II; D010622:Phencyclidine